SCHEMBL3979251

SCHEMBL3979251

NC(=O)c1ccc(Cl)cc1NC(=O)c1ccc(Br)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.56
TP53 P04637 1/20 0.54
ACLY P53396 1/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
PKM P14618 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MAPT P10636 2/20 0.52
KCNK2 O95069 1/20 0.51
KCNK10 P57789 1/20 0.51
KCNMA1 Q12791 2/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
HDAC1 Q13547 2/20 0.47
HDAC8 Q9BY41 2/20 0.47
HDAC6 Q9UBN7 2/20 0.47
PDCD1 Q15116 1/20 0.47
CD274 Q9NZQ7 1/20 0.47
SERPINE1 P05121 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28481464 0.91 MEN1 (0.58) GRIK1TP53MEN1KMT2APKM
SCHEMBL28487313 0.88 KCNK2 (0.56) TP53ACLYMEN1KMT2AMAPT
SCHEMBL1308714 0.77 MEN1 (0.76) GRIK1ACLYMEN1KMT2APKM
SCHEMBL3976985 0.76 MAPT (0.51) GRIK1TP53MEN1KMT2ANPSR1
SCHEMBL23831261 0.76 GRIK1 (0.61) GRIK1MEN1KMT2A
SCHEMBL11826793 0.76 PDCD1 (0.72) TP53MEN1KMT2ANPSR1NPC1
SCHEMBL23831517 0.74 GRIK1 (0.59) GRIK1MEN1KMT2A
SCHEMBL674168 0.74 KCNMA1 (0.66) GRIK1MEN1KMT2APKMNPSR1
SCHEMBL3619892 0.74 KMT2A (0.67) MEN1KMT2APKMNPSR1MAPT
SCHEMBL15305914 0.73 KMT2A (0.48) TP53MEN1KMT2APKMNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7547702-B2 4-amino-quinazolines ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2009-06-16 US disclosed
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents ORTHO-MCNEIL PHARMACEUTICALS, INC. 2006-01-26 US disclosed
WO-2004030672-A1 USE OF 4 AMINO-QUINAZOLINES AS ANTI CANCER AGENTS MERCK PATENT GMBH (DE) 2004-04-15 WO disclosed
CN-1474815-A 4-amino-quinazolines Ĭ��ר���ɷ����޹�˾ 2004-02-11 CN disclosed
EP-1318984-A1 4-AMINO-QUINAZOLINES MERCK PATENT GmbH (DE) 2003-06-18 EP disclosed
WO-2002024667-A1 4-AMINO-QUINAZOLINES MERCK PATENT GMBH (DE) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019974-A1 Glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents SERPINA3, APOL1, MGAT3 GRIK1 431/4885TP53 2851/4885ACLY 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.